PTC Therapeutics Inc.(PTCT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PTCT PTC Therapeutics Inc.

交易中 12-23 13:35:54 EST

45.28

-0.96

-2.08%

最高46.23	最低44.52	成交量18.15万
今开46.23	昨收46.24	日振幅3.70%
总市值34.92亿	流通市值27.49亿	总股本7,713万
成交额819.13万	换手率0.30%	流通股本6,071万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PTCT","market":"US","secType":"STK","nameCN":"PTC Therapeutics Inc.","latestPrice":45.28,"timestamp":1734978914630,"preClose":46.24,"halted":0,"volume":181493,"delay":0,"floatShares":60711046,"shares":77125143,"eps":-5.931042,"marketStatus":"交易中","marketStatusCode":2,"change":-0.96,"latestTime":"12-23 13:35:54 EST","open":46.23,"high":46.23,"low":44.52,"amount":8191279.103215001,"amplitude":0.036981,"askPrice":45.33,"askSize":111,"bidPrice":45.18,"bidSize":55,"shortable":3,"etf":0,"ttmEps":-5.931042,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1734987600000},"adr":0,"listingDate":1371700800000,"adjPreClose":46.24,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":46.3,"preClose":46.24,"latestTime":"08:21 EST","volume":221,"amount":10230.999857,"timestamp":1734960088778},"postHourTrading":{"tag":"盘后","latestPrice":46.2405,"preClose":46.24,"latestTime":"16:15 EST","volume":226977,"amount":10495416.884,"timestamp":1734729357592},"volumeRatio":0.385448,"impliedVol":0.6787,"impliedVolPercentile":0.5578},"requestUrl":"/m/hq/s/PTCT","defaultTab":"news","newsList":[{"id":"2490019466","title":"Ptc Therapeutics, Inc.盘中异动 快速拉升6.08%报50.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490019466","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490019466?lang=zh_cn&edition=full","pubTime":"2024-12-10 22:31","pubTimestamp":1733841077,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日22时31分，Ptc Therapeutics, Inc.股票出现波动，股价快速拉升6.08%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.25%。其相关个股中，Chimerix, Inc.、Uniqure N.V.、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大，Psyence Biomedical Ltd.、Processa Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为1643.12%、399.04%、84.92%，振幅较大的相关个股有Newamsterdam Pharma Company N.V.、Lava Therapeutics N.V.、Silexion Therapeutics Corp，振幅分别为10.21%、9.95%、9.70%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223117ab6cf51e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223117ab6cf51e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LENZ","PTCT","BK4139","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2488492247","title":"Ptc Therapeutics, Inc.盘中异动 下午盘股价大跌5.17%报49.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488492247","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488492247?lang=zh_cn&edition=full","pubTime":"2024-12-04 03:06","pubTimestamp":1733252760,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日03时06分，Ptc Therapeutics, Inc.股票出现异动，股价急速跳水5.17%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.80%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。消息层面，截至03时06分，《PTC Therapeutics与诺华制药签署亨廷顿病药物许可协议》资讯为影响Ptc Therapeutics, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204030600abf37014&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204030600abf37014&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PTCT","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","LENZ"],"gpt_icon":0},{"id":"2488966885","title":"美国研究综述-花旗集团、Salesforce、Zscaler","url":"https://stock-news.laohu8.com/highlight/detail?id=2488966885","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488966885?lang=zh_cn&edition=full","pubTime":"2024-12-03 15:11","pubTimestamp":1733209873,"startTime":"0","endTime":"0","summary":"美国研究综述-花旗集团、Salesforce、Zscaler路透社12月3日 - 华尔街证券分析师周二调整了对花旗集团、Salesforce 和 Zscaler 等多家美国上市公司的评级和目标价。* Salesforce Inc CRM.N：D.A. Davidson将目标价从250美元上调至300美元 * State Street Corp STT.N：KBW将其评级从 \"市场表现 \"上调至 \"跑赢大盘\"。* Zscaler Inc ZS.O：Piper Sandler将目标价从215美元上调至235美元以下是路透社周二报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nL3S3N40EV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGND","PTCT","RVMD","CRM","GEV","STT","C","HOLX","FDX","ARES","ZS"],"gpt_icon":1},{"id":"2488081066","title":"嗡嗡声--美国股票走势-Lululemon Athletica、邮轮股、超级微型公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2488081066","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488081066?lang=zh_cn&edition=full","pubTime":"2024-12-02 23:47","pubTimestamp":1733154473,"startTime":"0","endTime":"0","summary":"标准普尔 500 指数  百分比涨幅前三名是：** 超级微型计算机公司  ，上涨18.6%。** Upstart Holdings Inc   : BUZZ - 在摩根大通将其评级下调至 \"减持 \"后股价下跌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","CYTK","NOTE","DG","DOG","QLD","AMPX","NEM","NQmain","NVCR",".DJI","UDOW","D","PERF","EVEX","TPL","EQT","PCG","SDOW",".SPX","TQQQ","DDM","KSS","GAP","LU0312595415.SGD","CCL","PTCT","DJX","DXD","SQQQ","VYGR","SNTI","INTC","RCL","NCLH","FSLR","LEV","FSLY","MNQmain","PSQ","LULU","CORZ","EVTL","QID"],"gpt_icon":1},{"id":"2488708526","title":"Ptc Therapeutics, Inc.股价飙升15.43% 市值涨6.03亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488708526","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488708526?lang=zh_cn&edition=full","pubTime":"2024-12-02 22:31","pubTimestamp":1733149882,"startTime":"0","endTime":"0","summary":"北京时间2024年12月02日22时31分，Ptc Therapeutics, Inc.股票出现波动，股价大幅上涨15.43%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。其相关个股中，Senti Biosciences, Inc.、Purple Biotech Ltd、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Purple Biotech Ltd、Senti Biosciences, Inc.、Revelation Biosciences, Inc.较为活跃，换手率分别为643.05%、635.36%、201.02%，振幅较大的相关个股有Senti Biosciences, Inc.、Renovaro Inc.、Precigen, Inc.，振幅分别为16.20%、6.61%、6.40%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202223122a2669857&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202223122a2669857&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTCT","LU0109394709.USD","LU0320765992.SGD","BK4139","LENZ","LU0889565916.HKD"],"gpt_icon":0},{"id":"2488629674","title":"嗡嗡声--美国股票走势-英特尔、PTC Therapeutics、Senti Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2488629674","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488629674?lang=zh_cn&edition=full","pubTime":"2024-12-02 22:15","pubTimestamp":1733148927,"startTime":"0","endTime":"0","summary":"** Eve Holding Inc   : BUZZ - 宣布追加 3500 万美元用于 eVTOL 开发，股价上涨   ** Dollar General Corp   : BUZZ - 泰尔西咨询集团下调 Dollar General PT，原因是需求下降、竞争加剧   ** PTC Therapeutics Inc   : BUZZ - 因与诺华公司签订高达 29 亿美元的许可协议而股价上涨   ** Mara Holdings Inc   : BUZZ - 宣布计划发行 7 亿美元可转换债券，比特币开采最新进展；股价下跌   ** Dominion Energy Inc   : BUZZ - 摩根士丹利恢复对 Dominion Energy 的 \"等权重 \"评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4103","LU2506951792.HKD","LU2506952410.USD","LU1223082519.USD","LENZ","LU0312595415.SGD","LU2294711713.HKD","NVCR","LU0055631609.USD","AFRM","LU0724618789.USD","INTC","PCG","VYGR","PTC","BK4532","IE00BZ18W340.USD","BK4141","D","BK4082","LU0368265764.SGD","EVEX","LU0496367417.USD","NEM","BK4116","BK4596","KSS","LU2506952337.HKD","LU2322448957.HKD","LU0654597011.USD","PTCT","FSLR","LU2462611646.USD","BK4588","CORZ","BK4512","LU2272731782.SGD","SNTI","BK4106","LU1992135399.USD","LU0498741890.SGD","BK4114","LU0823434583.USD","BK4600","BK4527","NOTE","DG","LU1430597077.USD"],"gpt_icon":1},{"id":"2488067958","title":"PTC Therapeutics(PTCT.US)与诺华制药(NVS.US)签署亨廷顿病药物许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2488067958","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488067958?lang=zh_cn&edition=full","pubTime":"2024-12-02 21:23","pubTimestamp":1733145808,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国生物制药公司PTC Therapeutics的股价周一盘前上涨21%，此前该公司与诺华制药签署了PTC518亨廷顿病项目的独家全球许可和合作协议。PTC518目前正在进行2期PIVOT-HD试验，并显示出良好的安全性和耐受性。该协议预计将于2025年第一季度完成。根据协议，PTC Therapeutics 将获得10亿美元的预付款，高达19亿美元的开发、监管和销售里程碑，在美国的利润分成为40%，并在美国以外的地区获得两位数的销售分层版税。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0109394709.USD","BK4588","LU0211331839.USD","IE0002141913.USD","IE00B2B36J28.USD","LU1923623000.USD","BK4554","LU1951200564.SGD","LU1721428347.USD","LU2506952337.HKD","NVS","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","BK1574","PTC","BK4023","01477","BK4578","IE00B4R5TH58.HKD","LU2362541513.USD","BK4007","LENZ","BK4139","LU1951198990.SGD","PTCT","LU2506952410.USD","LU0889565916.HKD","LU2362540622.SGD","BK4576","LU2362541273.HKD","LU2477742899.HKD","BK4532","BK4585","LU0320765992.SGD","BK1191","IE0009355771.USD"],"gpt_icon":0},{"id":"2488967568","title":"BUZZ-PTC Therapeutics 因与诺华签署高达 29 亿美元的许可协议而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2488967568","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488967568?lang=zh_cn&edition=full","pubTime":"2024-12-02 20:40","pubTimestamp":1733143219,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    12月2日 - ** PTC Therapeutics   股价盘前上涨20.5%至52.89美元 ** 该公司称制药商诺华  将为PTCT的候选药物PTC518支付10亿美元预付款和最多19亿美元的里程碑付款，该药物正在开发中，用于治疗亨廷顿氏症** NOVN 将负责该药物的开发、生产和商业化。** PTCT 和 NOVN 将分别按 40/60 的比例分享该药物在美国的利润和损失** 截至上一交易日收盘，股价累计上涨 59.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1951200564.SGD","PTC","IE0009355771.USD","LU2506952410.USD","LU2506952337.HKD","LENZ","BK4585","IE00BFTCPJ56.SGD","LU1951198990.SGD","PTCT","BK4532","IE0002141913.USD","BK4554","LU2362541513.USD","BK4578","IE00B4R5TH58.HKD","LU0109394709.USD","LU2362541273.HKD","BK4588","BK4023","IE00BJT1NW94.SGD","LU0211331839.USD","NVS","BK4576","BK4007","LU1923623000.USD","LU2362540622.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU2477742899.HKD","IE00B2B36J28.USD","LU1721428347.USD","LU0320765992.SGD","BK4139"],"gpt_icon":0},{"id":"2488967535","title":"更新版 1-更正-PTC Therapeutics 与诺华签订价值 29 亿美元的许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2488967535","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488967535?lang=zh_cn&edition=full","pubTime":"2024-12-02 20:35","pubTimestamp":1733142942,"startTime":"0","endTime":"0","summary":"     路透社12月2日 - PTC Therapeutics   已与诺华公司  签署了一项高达29亿美元的许可协议，用于该美国公司治疗一种罕见神经系统疾病的实验性药物，这使其股价在周一的盘前交易中上涨了20%。诺华公司将为 PTC 的候选药物 PTC518 提供 10 亿美元的预付款和高达 19 亿美元的里程碑付款，PTC518 正在开发中，用于治疗亨廷顿氏症。PTC 和诺华将分别按 40/60 的比例分享该药在美国的利润和损失。两家公司预计交易将于 2025 年第一季度完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1951198990.SGD","BK4139","LENZ","LU1721428347.USD","BK4023","IE00BJT1NW94.SGD","LU2506952410.USD","LU2362541273.HKD","BK4588","PTC","IE00B2B36J28.USD","LU0109394709.USD","LU2506952337.HKD","BK4578","BK4532","LU2477742899.HKD","LU0320765992.SGD","BK4554","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","BK4585","IE00BFTCPJ56.SGD","LU1951200564.SGD","LU2362541513.USD","IE0002141913.USD","NVS","IE00B4R5TH58.HKD","LU0889565916.HKD","PTCT","LU1923623000.USD","BK4576","LU2362540622.SGD","BK4007"],"gpt_icon":0},{"id":"2488733116","title":"PTC Therapeutics 与诺华签订高达 19 亿美元的许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2488733116","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488733116?lang=zh_cn&edition=full","pubTime":"2024-12-02 20:10","pubTimestamp":1733141414,"startTime":"0","endTime":"0","summary":"PTC Therapeutics 与诺华签订高达 19 亿美元的许可协议路透社12月2日 - PTC Therapeutics PTCT.O公司周一表示，该公司已与诺华集团NOVN.S旗下的一家公司达成了一项高达19亿美元的许可协议，用于开发治疗一种罕见神经系统疾病的实验性药物。 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nL3T3N30OL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0889565916.HKD","LU0109394709.USD","PTCT","LU0320765992.SGD"],"gpt_icon":0},{"id":"2486748648","title":"BUZZ-PTC Therapeutics放弃开发ALS药物后股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2486748648","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486748648?lang=zh_cn&edition=full","pubTime":"2024-11-28 00:42","pubTimestamp":1732725731,"startTime":"0","endTime":"0","summary":"** 包括盘中走势在内，该股今年累计上涨约 64 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nL3T3MY163:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139","PTCT"],"gpt_icon":0},{"id":"2486374748","title":"PTC Therapeutics 在试验失败后停止开发 ALS 药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2486374748","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486374748?lang=zh_cn&edition=full","pubTime":"2024-11-27 05:53","pubTimestamp":1732658014,"startTime":"0","endTime":"0","summary":"更新版 1-PTC Therapeutics 在试验失败后停止开发 ALS 药物第2段增加了试验细节，第3段增加了背景，第4段增加了股票走势路透社11月26日 - PTC Therapeutics PTCT.O周二表示，由于在一项中期试验中没有达到主要目标，该公司将停止开发治疗一种致命神经退行性疾病的药物。美国有 1.6 万至 3.2 万名 ALS 患者，长期以来，研究人员一直在寻找有效的治疗方法。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nL3S3MX1RS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4139","PTCT","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2486450832","title":"PTC Therapeutics 公司的 ALS 药物中期试验失败","url":"https://stock-news.laohu8.com/highlight/detail?id=2486450832","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486450832?lang=zh_cn&edition=full","pubTime":"2024-11-27 05:37","pubTimestamp":1732657033,"startTime":"0","endTime":"0","summary":"PTC Therapeutics 公司的 ALS 药物中期试验失败路透社11月26日 - PTC Therapeutics PTCT.O周二表示，它的药物在一项中期试验中没有达到主要目标，该试验对一种致命的神经退行性疾病肌萎缩性脊髓侧索硬化症患者进行了评估。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nL3T3MX1QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","PTCT","LU0889565916.HKD","BK4139","LU0320765992.SGD"],"gpt_icon":0},{"id":"2486888002","title":"Ptc Therapeutics, Inc.盘中异动 早盘快速上涨5.08%报45.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486888002","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486888002?lang=zh_cn&edition=full","pubTime":"2024-11-26 22:40","pubTimestamp":1732632005,"startTime":"0","endTime":"0","summary":"北京时间2024年11月26日22时40分，Ptc Therapeutics, Inc.股票出现异动，股价快速上涨5.08%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.47%。其相关个股中，Poseida Therapeutics, Inc.、Fate Therapeutics, Inc.、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 涨幅较大，Oncternal Therapeutics, Inc.、Poseida Therapeutics, Inc.、木薯科学较为活跃，换手率分别为15.10%、12.22%、11.24%，振幅较大的相关个股有Protagenic Therapeutics, Inc.、Cabaletta Bio, Inc.、Fate Therapeutics, Inc.，振幅分别为21.66%、19.65%、16.32%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112622400598e44aad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112622400598e44aad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","PTCT","LU0889565916.HKD","LU0109394709.USD","BK4139","LU0320765992.SGD"],"gpt_icon":0},{"id":"2486059932","title":"Biohaven 的脊髓性肌肉萎缩症药物未能达到研究目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2486059932","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486059932?lang=zh_cn&edition=full","pubTime":"2024-11-26 03:06","pubTimestamp":1732561590,"startTime":"0","endTime":"0","summary":"更新 3-Biohaven 的脊髓性肌肉萎缩症药物未能达到研究目标第 1 段增加了岩石学者股份，第 9 段增加了分析师评论Mariam Sunny. Biohaven的治疗药物taldefgrobep alfa正在脊髓性肌萎缩症患者中进行试验，这是全球婴儿死亡的主要遗传原因。Biohaven对269名年龄在4至21岁之间、患有任何SMA类型的参与者进行了测试，无论其行走能力如何。Biohaven公司计划在2024年第四季度开始一项中期研究，测试该药物治疗肥胖症的潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nL3T3MW0TY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B894F039.SGD","BK4139","BK4585","LU0234570918.USD","LU0889565916.HKD","LU1093756168.USD","LU0109394709.USD","LU0320765992.SGD","BK4533","IE00B19Z9P08.USD","PTCT","BK4532","BIIB","LU1093756325.SGD","SRRK","BK4588","BHVN","IE00B19Z9Z06.USD"],"gpt_icon":0},{"id":"2484960389","title":"美国研究综述-Equifax、Microstrategy、Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=2484960389","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484960389?lang=zh_cn&edition=full","pubTime":"2024-11-19 15:10","pubTimestamp":1732000212,"startTime":"0","endTime":"0","summary":"美国研究综述-Equifax、Microstrategy、Netflix路透11月19日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Equifax、Microstrategy 和 Netflix。要闻  * 凯斯百货公司CASY.O：杰富瑞将目标价从 450 美元上调至 470 美元 * Equifax Inc EFX.N：摩根大通将目标价从304美元下调至283美元 * Microstrategy Inc MSTR.O：Benchmark将目标价从300美元上调至450美元 * Netflix Inc NFLX.O：杰富瑞将目标价从800美元上调至1000美元 * Palo Alto Networks Inc PANW.O：杰富瑞将目标价从400美元上调至450美元以下是路透周二报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nL4S3MQ0JJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEOH","KHC","CPRX","LU1429558221.USD","IDYA","LU1571399168.USD","LU0106261372.USD","MSTR","LU2237957902.USD","CGEM","EFX","LU0109394709.USD","CASY","MRNA","MOS","FNV","LU2249611893.SGD","BK4107","PTCT","EHAB","LU2326559502.SGD","CCCC","FENC","RDDT","PANW","CHPT","VRT","FTNT","LOVE","CPRT","DCOM","ARVN","NFLX","WSM","RC","ACRS","IE00BQXX3C00.GBP","RGNX","BK4588","LU1046421795.USD","PLUG","BK4077","KMPR","LU1670710661.SGD","BK4113","BECN","KYMR","BK4585","QS"],"gpt_icon":1},{"id":"2484404510","title":"Ptc Therapeutics, Inc.2024财年第三财季实现净利润-1.07亿美元，同比增加19.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484404510","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484404510?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:02","pubTimestamp":1731772933,"startTime":"0","endTime":"0","summary":"11月17日，Ptc Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-1.07亿美元，同比增加19.55%；其中营业收入为1.97亿美元，同比增加0.00%，每股基本收益为-1.39美元。从资产负债表来看，Ptc Therapeutics, Inc.总负债28.97亿美元，其中短期债务16.76百万美元，资产负债比为0.64，流动比率为2.10。机构评级：截至2024年11月17日，当前有14家机构对Ptc Therapeutics, Inc.目标价做出预测，其中目标均价为44.21美元，其中最低目标价为26.00美元，最高目标价为66.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000313a23e063c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000313a23e063c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTCT","LENZ"],"gpt_icon":0},{"id":"2483198875","title":"BUZZ-PTC Therapeutics 因其基因疗法获 FDA 批准而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2483198875","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483198875?lang=zh_cn&edition=full","pubTime":"2024-11-14 19:54","pubTimestamp":1731585257,"startTime":"0","endTime":"0","summary":"11月14日 -  ** 制药商PTC Therapeutics PTCT.O股价盘前上涨3.3%，报45.50美元 ** 本周三，美国食品和药物管理局批准了  PTCT 的基因疗法 Kebilidi，用于治疗一种可能致命的酶缺乏症--芳香族 L-氨基酸脱羧酶 缺乏症。** 鉴于 AADC 患者人数有限，William Blair 分析师预计 2026 年产品收入峰值为 2.663 亿美元。** AADC 缺乏症是一种遗传性疾病，会影响大脑产生多巴胺和血清素的能力，而多巴胺和血清素对运动功能至关重要。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL4S3ML16T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4139","PTCT","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2483320861","title":"美国 FDA 批准 PTC Therapeutics 用于治疗超罕见疾病的基因疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2483320861","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483320861?lang=zh_cn&edition=full","pubTime":"2024-11-14 07:06","pubTimestamp":1731539186,"startTime":"0","endTime":"0","summary":"美国 FDA 批准 PTC Therapeutics 用于治疗超罕见疾病的基因疗法路透11月13日 - PTC Therapeutics公司周三表示，美国食品和药物管理局批准了该公司的PTCT.O基因疗法，该疗法可直接在大脑中施用，用于治疗一种潜在的致命性酶缺乏症。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL4T3MK28E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","PTCT","LU0889565916.HKD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2481010241","title":"Ptc Therapeutics, Inc.盘中异动 早盘快速拉升6.24%报45.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481010241","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481010241?lang=zh_cn&edition=full","pubTime":"2024-11-08 22:31","pubTimestamp":1731076293,"startTime":"0","endTime":"0","summary":"北京时间2024年11月08日22时31分，Ptc Therapeutics, Inc.股票出现异动，股价快速拉升6.24%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.56%。其相关个股中，Fortrea Holdings Inc.、Poseida Therapeutics, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Elevai Labs, Inc.、Matinas Biopharma Holdings, Inc.、Lipella Pharmaceuticals Inc.较为活跃，换手率分别为371.30%、16.25%、13.55%，振幅较大的相关个股有Anebulo Pharmaceuticals, Inc.、Cardiff Oncology, Inc.、Sab Biotherapeutics, Inc.，振幅分别为14.96%、13.20%、11.62%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110822313395bdeed4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110822313395bdeed4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","PTCT","BK4139","LENZ","LU0889565916.HKD","LU0320765992.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ptcbio.com","stockEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.102},{"period":"3month","weight":0.262},{"period":"6month","weight":0.2662},{"period":"1year","weight":0.627},{"period":"ytd","weight":0.6778}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ptc Therapeutics, Inc.于1998年3月31日注册成立为一家特拉华州公司。 PTC Therapeutics股份有限公司是一家生物制药公司，专注于用于转录后控制过程中的口服药，专有的小分子药物的发现和开发。同时该公司的研发计划针对于多个治疗领域，公司特别专注于孤儿和超孤儿混乱疾病的治疗的开发和商业化。公司主导的候选产品是ataluren，该产品用于治疗过程中所出现的一种被称为无义突变基因突变的遗传性疾病的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.108578},{"month":2,"riseRate":0.545455,"avgChangeRate":-0.006897},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.072507},{"month":4,"riseRate":0.545455,"avgChangeRate":0.029187},{"month":5,"riseRate":0.545455,"avgChangeRate":0.027228},{"month":6,"riseRate":0.545455,"avgChangeRate":0.056583},{"month":7,"riseRate":0.636364,"avgChangeRate":0.023181},{"month":8,"riseRate":0.75,"avgChangeRate":0.072316},{"month":9,"riseRate":0.5,"avgChangeRate":0.021861},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.090754},{"month":11,"riseRate":0.666667,"avgChangeRate":0.124131},{"month":12,"riseRate":0.666667,"avgChangeRate":0.045895}],"exchange":"NASDAQ","name":"PTC Therapeutics Inc.","nameEN":"PTC Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PTC Therapeutics Inc.(PTCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PTC Therapeutics Inc.(PTCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PTC Therapeutics Inc.,PTCT,PTC Therapeutics Inc.股票,PTC Therapeutics Inc.股票老虎,PTC Therapeutics Inc.股票老虎国际,PTC Therapeutics Inc.行情,PTC Therapeutics Inc.股票行情,PTC Therapeutics Inc.股价,PTC Therapeutics Inc.股市,PTC Therapeutics Inc.股票价格,PTC Therapeutics Inc.股票交易,PTC Therapeutics Inc.股票购买,PTC Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PTC Therapeutics Inc.(PTCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PTC Therapeutics Inc.(PTCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}